New vaccine combo aims to train immune system to fight bladder cancer
NCT ID NCT05843448
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing a new peptide vaccine (IO102-IO103) combined with the immunotherapy drug pembrolizumab (Keytruda) in 30 adults with high-risk non-muscle invasive bladder cancer that did not respond to or could not tolerate standard BCG therapy. The vaccine is designed to activate the body's T-cells to recognize and attack cancer cells, while pembrolizumab helps remove brakes on the immune system. The main goal is to check safety and side effects, with a secondary goal of seeing if the cancer disappears completely.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PD-L1/IDO peptide vaccine (IO102-IO103) and pembrolizumab (Keytruda)
What this could lead to
If this combination works, it could offer a new treatment option for people with bladder cancer that hasn't responded to standard therapy, potentially avoiding the need for bladder removal.
What could go wrong
This is a very early phase 1 trial with only 30 participants, so it's primarily testing safety. The vaccine may not work as hoped, and side effects from the immune-boosting drugs could be serious.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE 0A BLADDER CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of California Davis Comprehensive Cancer Center
RECRUITINGSacramento, California, 95817, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••